Literature DB >> 9061037

Mutually co-operative interactions between modulators of P-glycoprotein.

Y M Shao1, S Ayesh, W D Stein.   

Abstract

We measured the effects of combinations of verapamil, vinblastine, mefloquine, and tamoxifen, all being modulators of the multidrug resistance pump, P-glycoprotein, on the accumulation of labelled daunomycin into multidrug-resistant P388 leukemia cells at 37 degrees C. We found that, contrary to our initial expectations (based on Ayesh, Shao and Stein (1996) Biochim. Biophys. Acta 1316, 8), vinblastine, mefloquine, and tamoxifen all appeared to interact with one another synergistically, i.e. by the kinetics of a non-competitive interaction. A simple kinetic analysis showed that pairs of co-operating modulators can give apparent non-competitive behaviour, but refined kinetic analysis enables the two types of interaction to be distinguished. The modulators vinblastine, mefloquine, and tamoxifen thus appear to co-operate with one another in pairs to bring about reversal of P-glycoprotein. This may have important implications for the design of new modulators of P-glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9061037     DOI: 10.1016/s0925-4439(96)00065-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  The enantioselective binding of mefloquine enantiomers to P-glycoprotein determined using an immobilized P-glycoprotein liquid chromatographic stationary phase.

Authors:  L Lu; F Leonessa; M T Baynham; R Clarke; F Gimenez; Y T Pham; F Roux; I W Wainer
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

2.  Interactions of mefloquine with ABC proteins, MRP1 (ABCC1) and MRP4 (ABCC4) that are present in human red cell membranes.

Authors:  Chung-Pu Wu; Antonios Klokouzas; Stephen B Hladky; Suresh V Ambudkar; Margery A Barrand
Journal:  Biochem Pharmacol       Date:  2005-08-15       Impact factor: 5.858

3.  The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein.

Authors:  C Martin; G Berridge; P Mistry; C Higgins; P Charlton; R Callaghan
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

4.  Structural mechanism of the simultaneous binding of two drugs to a multidrug-binding protein.

Authors:  Maria A Schumacher; Marshall C Miller; Richard G Brennan
Journal:  EMBO J       Date:  2004-07-15       Impact factor: 11.598

Review 5.  Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators.

Authors:  Ahmad R Safa
Journal:  Curr Med Chem Anticancer Agents       Date:  2004-01

6.  Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice.

Authors:  Sylvie Barraud de Lagerie; Emmanuelle Comets; Céline Gautrand; Christine Fernandez; Daniel Auchere; Eric Singlas; France Mentre; François Gimenez
Journal:  Br J Pharmacol       Date:  2004-03-15       Impact factor: 8.739

7.  Structure-activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein.

Authors:  Ishrat Jabeen; Karin Pleban; Uwe Rinner; Peter Chiba; Gerhard F Ecker
Journal:  J Med Chem       Date:  2012-03-27       Impact factor: 7.446

8.  Active transport of rhodamine 123 by the human multidrug transporter P-glycoprotein involves two independent outer gates.

Authors:  Fauzia Nasim; Diethart Schmid; Gergely Szakács; Azmat Sohail; Harald H Sitte; Peter Chiba; Thomas Stockner
Journal:  Pharmacol Res Perspect       Date:  2020-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.